Acorda Therapeutics Makes All Cash Offer To Biotie Therapies
Edison | Jan 20, 2016 07:19AM ET
Biotie Therapies Oyj (HE:BTH1V) strikes Acord(a) with PD franchise
Acorda Therapeutics has made an all-cash offer for Biotie at €0.2946 per share, a 95% premium to the previous close price, valuing the company at €321m (ex. options). Our last published valuation was €0.28/share. The timing of the deal is relevant in the context that the primary Phase III study for tozadenant in Parkinson’s disease (PD) patients is in early stages of recruitment and preliminary data are not expected until end 2017. Biotie’s board has recommended the offer and shareholders representing 59% of the outstanding shares have undertaken to accept Acorda’s proposal.
Following highly positive results from a pivotal 240-patient Phase IIb with tozadenant, an orally potent and selective adenosine A2a receptor antagonist, Biotie initiated a 450-patient Phase III study (TOZ-PD) in July 2015 in mild- to moderate-PD patients experiencing motor fluctuations on levodopa. With estimated cash of €74m at end 2015, Biotie had sufficient funds to complete the TOZ-PD to data read-out by end 2017/early 2018, but not to fund the requisite second Phase III safety study, to be initiated post TOZ-PD read-out, to generate the 1,500 unique patient exposures required to gain FDA approval.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.